Clinical reviews

LINERIXIBAT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND CHOLESTATIC PRURITUS (GLISTEN): A RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL

GLISTEN Study Group

PDF202512 pages1.7 MB

Cholestatic pruritus is a common and often undertreated symptom in patients with primary biliary cholangitis, significantly impacting their quality of life. The GLISTEN study aimed to assess the efficacy of linerixibat in alleviating pruritus in these patients. Conducted across 115 centers in 19 countries, the trial involved a randomized, double-blind, placebo-controlled design, focusing on patients with moderate-to-severe pruritus. The primary endpoint was the change in pruritus severity over 24 weeks, measured using the Worst Itch Numerical Rating Scale (WI-NRS).

Ask this resource

Answers use this document only.

Your first question is free.

LINERIXIBAT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND CHOLESTATIC PRURITUS (GLISTEN): A RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL

Ask this resource

More like this

Clinical Resources

LINERIXIBAT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND CHOLESTATIC PRURITUS (GLISTEN): A RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL

Ask this resource

More like this

Clinical Resources